ViGenCell Statistics
Total Valuation
ViGenCell has a market cap or net worth of KRW 63.19 billion. The enterprise value is 25.90 billion.
| Market Cap | 63.19B |
| Enterprise Value | 25.90B |
Important Dates
The last earnings date was Thursday, August 14, 2025.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ViGenCell has 20.45 million shares outstanding. The number of shares has increased by 1.14% in one year.
| Current Share Class | 20.45M |
| Shares Outstanding | 20.45M |
| Shares Change (YoY) | +1.14% |
| Shares Change (QoQ) | +1.28% |
| Owned by Insiders (%) | 11.89% |
| Owned by Institutions (%) | n/a |
| Float | 13.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 226.52 |
| PB Ratio | 1.11 |
| P/TBV Ratio | 1.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.06 |
| EV / Sales | 92.83 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.85 |
Financial Position
The company has a current ratio of 5.77, with a Debt / Equity ratio of 0.14.
| Current Ratio | 5.77 |
| Quick Ratio | 5.73 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.85 |
| Interest Coverage | -37.45 |
Financial Efficiency
Return on equity (ROE) is -20.23% and return on invested capital (ROIC) is -12.17%.
| Return on Equity (ROE) | -20.23% |
| Return on Assets (ROA) | -11.91% |
| Return on Invested Capital (ROIC) | -12.17% |
| Return on Capital Employed (ROCE) | -23.36% |
| Revenue Per Employee | 4.36M |
| Profits Per Employee | -196.23M |
| Employee Count | 64 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +17.49% in the last 52 weeks. The beta is 1.05, so ViGenCell's price volatility has been similar to the market average.
| Beta (5Y) | 1.05 |
| 52-Week Price Change | +17.49% |
| 50-Day Moving Average | 3,573.90 |
| 200-Day Moving Average | 3,201.35 |
| Relative Strength Index (RSI) | 36.04 |
| Average Volume (20 Days) | 49,514 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ViGenCell had revenue of KRW 278.95 million and -12.56 billion in losses. Loss per share was -650.72.
| Revenue | 278.95M |
| Gross Profit | 4.30M |
| Operating Income | -13.56B |
| Pretax Income | -12.56B |
| Net Income | -12.56B |
| EBITDA | -10.23B |
| EBIT | -13.56B |
| Loss Per Share | -650.72 |
Balance Sheet
The company has 45.02 billion in cash and 7.72 billion in debt, giving a net cash position of 37.29 billion or 1,823.64 per share.
| Cash & Cash Equivalents | 45.02B |
| Total Debt | 7.72B |
| Net Cash | 37.29B |
| Net Cash Per Share | 1,823.64 |
| Equity (Book Value) | 56.72B |
| Book Value Per Share | 2,790.82 |
| Working Capital | 37.61B |
Cash Flow
In the last 12 months, operating cash flow was -8.98 billion and capital expenditures -100.04 million, giving a free cash flow of -9.08 billion.
| Operating Cash Flow | -8.98B |
| Capital Expenditures | -100.04M |
| Free Cash Flow | -9.08B |
| FCF Per Share | -444.10 |
Margins
| Gross Margin | 1.54% |
| Operating Margin | -4,861.71% |
| Pretax Margin | -4,502.18% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ViGenCell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.14% |
| Shareholder Yield | -1.14% |
| Earnings Yield | -19.88% |
| FCF Yield | -14.37% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 8, 2022. It was a forward split with a ratio of 2.
| Last Split Date | Jun 8, 2022 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
ViGenCell has an Altman Z-Score of 2.21 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.21 |
| Piotroski F-Score | 1 |